Blepharitis Clinical Trials 2023

Blepharitis Clinical Trials 2023

Blepharitis research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in blepharitis clinical trials today.

Popular filter options for blepharitis trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to blepharitis

What are the top hospitals conducting blepharitis research?

When it comes to advancing treatment options for blepharitis, several hospitals are leading the way in conducting clinical trials. In Northridge, California, Shultz Chang Vision is at the forefront with one ongoing trial and a total of two blepharitis trials conducted thus far. This eye clinic made its first foray into blepharitis research just last year in 2021. Likewise, Vita Eye Clinic in Shelby, Ohio is actively involved in investigating this condition with one current trial and three previous studies under their belt; their initial exploration of blepharitis dates back to 2020.

Moving over to Boulder, Colorado, the University of Colorado is making significant contributions as well. With one active trial and a single past study focusing on blepharitis since commencing their research journey also in 2020.They have been working tirelessly towards better understanding and management of this distressing eye condition. Further eastward lies Michiana Eye Center located Mishawaka Indiana where they too dedicate themselves toward progressing our knowledge regarding such ailments through a singular present investigation paired with equally notable findings from their inaugural probe recorded specifically onblepharitischallengs during year ago starting from same mentioned date likewise Kentucky Eye Institute situated Lexington has shown dedication by exploring incredible revelations within complex realms associated studying this particular ophthalmologic concern contributing directly via an ongoing investigative effort along with prior achievements resulting collective data derived since committing efforts known from that memorable calendar period.

Although these hospitals may have fewer trials compared to larger institutions or other conditions under scrutiny,researchers at these medical centers are committed to pushing boundaries and seeking innovative solutions for patients suffering from blepharitis. Through their dedicated efforts,fresh insights can emerge,and new treatments will be developedto alleviate the discomfort caused by this common eyelid inflammation.We celebrate every small step taken towards improving ocular health,the vision clarity which ensures brighter future outlooksfor countless individuals worldwide

Which are the best cities for blepharitis clinical trials?

When it comes to blepharitis clinical trials, several cities offer opportunities for individuals seeking innovative treatments. Northridge, California; Shelby, North carolina; Boulder, Colorado; Mishawaka, Indiana; and Lexington, Kentucky each have one active trial focused on this condition. These trials investigate different aspects such as Study Cohort 1 or Treatment Group with the aim of advancing our understanding and management of blepharitis. While these are not exhaustive lists, individuals in these cities can explore participation in these localized trials to potentially benefit from new approaches and contribute to scientific progress in treating blepharitis.

Which are the top treatments for blepharitis being explored in clinical trials?

In the realm of blepharitis, clinical trials are shedding light on potential breakthrough treatments. Among them, three standout contenders have emerged:

  • Azithromycin: Showing promise in effectively combating this eye condition.
  • Doxycycline: Being explored as a possible therapeutic option for managing blepharitis.
  • Warm compress therapy: Gaining attention as a non-pharmacological approach to alleviate symptoms.

As researchers delve deeper into these treatments through ongoing trials, hope grows for improved outcomes and relief for individuals affected by blepharitis.

What are the most recent clinical trials for blepharitis?

Exciting developments in the field of blepharitis are underway, with recent clinical trials offering potential breakthroughs in treatment. Phase 2 trial Study Cohort 1 has recently become available, showcasing promising advancements for this condition. As researchers continue to explore new avenues and interventions, these trials provide hope for improved management strategies and relief for those suffering from blepharitis. Stay tuned as further discoveries emerge to transform the landscape of care for this common eye disorder.

What blepharitis clinical trials were recently completed?

A recent milestone in the field of blepharitis treatment was reached with the completion of a clinical trial for TP-03, sponsored by Tarsus Pharmaceuticals, Inc., in April 2021. This trial holds great promise in advancing our understanding and management of blepharitis, offering potential new therapeutic options for this common eye condition characterized by eyelid inflammation. The successful completion of this study marks an important step forward in addressing the needs of patients suffering from blepharitis and may pave the way for more effective treatments in the future.